You are here

AstraZeneca spins off autoimmune drugs into new biotech company

London

ASTRAZENECA is spinning off six early-stage experimental drugs into a new US$250 million stand-alone biotech company focused on severe autoimmune diseases.

The spin-off of the three clinical and three pre-clinical biological compounds, announced on Wednesday, is the latest

sentifi.com

Market voices on: